MK-1775isaninhibitorofWee1,aproteinthatregulatestheG2mitosischeckpointinresponsetoDNAdamage.MK-1775exhibitsanticancerchemotherapeuticactivity.Inacutemyelogenousleukemia(AML)cells,thiscompounddecreasesphosphorylationofCDK1/2andinducesdouble-strandedDNAbreaks.Inanimalmodelsofvariouscancers,MK-1775increasessurvivaltimesanddecreasestumorsize,particularlywhenco-admiNISTeredwithothertreatments.
| CasNo. | 955365-80-7 |
|---|---|
| Purity | ≥98% |
| Formula | C27H32N8O2 |
| FormulaWt. | 500.60 |
| IUPACName | 2-Allyl-1-[6-(2-hydroxy-2-propanyl)-2-pyridinyl]-6-{[4-(4-methyl-1-piperazinyl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one |
| Appearance | Paleyellowpowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | M4102InfoSheetPDF |
|---|
QiW,XieC,LiC,etal.CHK1playsacriticalroleintheanti-leukemicactivityofthewee1inhibitorMK-1775inacutemyeloidleukemiacells.JHematolOncol.2014Aug1;7:53.PMID:25084614.
VanLindenAA,BaturinD,FordJB,etal.InhibitionofWee1sensitizescancercellstoantimetabolitechemotherapeuticsinvitroandinvivo,independentofp53functionality.MolCancerTher.2013Dec;12(12):2675-84.PMID:24121103.
HiraiH,IwasawaY,OkadaM,etal.Small-moleculeinhibitionofWee1kinasebyMK-1775selectivelysensitizesp53-deficienttumorcellstoDNA-damagingagents.MolCancerTher.2009Nov;8(11):2992-3000.PMID:19887545.
